"The Long Run"
Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina, and resilience, to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Ep90: James Sabry on Partnering Amid Scientific Abundance
James Sabry, global head of pharma partnering for Roche, on partnering in a time of scientific abundance.
Ep89: Emily Leproust on DNA Synthesis at Scale
Emily Leproust, co-founder and CEO of Twist Bioscience, on DNA Synthesis at Scale
Ep88: Amy DuRoss on software and logistics for cell and gene therapy
Amy DuRoss, CEO of Vineti, on software and logistics for cell and gene therapy.
Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing
Bob Nelsen of ARCH Venture Partners on long-term trends in biotech investing.
Ep86: Sek Kathiresan on a Gene-Edited Single Shot for Heart Disease
Sekar Kathiresan, co-founder and CEO of Verve Therapeutics, on a gene edited single shot for cardiovascular disease.
Ep85: Luhan Yang on CRISPR Editing for Organ Transplants
Luhan Yang, CEO of Qihan Bio, on CRISPR editing for organ transplants.